Cost-Effectiveness Analysis of Camrelizumab Immunotherapy versus Docetaxel or Irinotecan Chemotherapy as Second-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Overview of attention for article published in Cancer Management and Research, November 2021

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 11 Dimensions

Readers on

mendeley: 9 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 1,424 followers.

Second-line therapy for advanced or metastatic ESCC | CMAR - Dove Medical Press https://t.co/LQaLwmlNCZ

Reply Repost Favourite